Lifeboat Foundation

The technical challenges are not as daunting as the social and diplomatic ones, says bioengineer Kevin Esvelt at the Massachusetts Institute of Technology (MIT) Media Lab in Cambridge, who was among the first to build a CRISPR-based gene drive. “Technologies like this have real-world consequences for people’s lives that can be nearly immediate.”

Altering the genomes of entire animal populations could help to defeat disease and control pests, but researchers worry about the consequences of unleashing this new technology.

Despite their names, artificial intelligence technologies and their component systems, such as artificial neural networks, don’t have much to do with real brain science. I’m a professor of bioengineering and neurosciences interested in understanding how the brain works as a system – and how we can use that knowledge to design and engineer new machine learning models.

In recent decades, brain researchers have learned a huge amount about the physical connections in the brain and about how the nervous system routes information and processes it. But there is still a vast amount yet to be discovered.

At the same time, computer algorithms, software and hardware advances have brought machine learning to previously unimagined levels of achievement. I and other researchers in the field, including a number of its leaders, have a growing sense that finding out more about how the brain processes information could help programmers translate the concepts of thinking from the wet and squishy world of biology into all-new forms of machine learning in the digital world.

Introducing the SBOL Industrial Consortium

To this end, a group of companies are now launching a pre-competitive consortium to support the industrial application of these technologies. The SBOL Industrial Consortium is a non-profit organization supporting innovation, dissemination, and integration of SBOL standards, tools and practices for practical applications in an industrial environment. The six founding companies of the consortium are Raytheon BBN Technologies, Amyris, Doulix, IDT, Shipyard Toolchains, TeselaGen, and Zymergen, representing a diverse set of interests and business models across the synthetic biology community.

The SBOL Industrial Consortium will facilitate industry-focused development of representational technologies in several ways. The consortium will help coordinate development of standards and tools, both with the academic community and from member to member, in order to ensure that the SBOL standards are well-tuned to support the specific industrial needs of the members of the consortium. Financial support will also be provided by the consortium for selected projects and activities, and for key pieces of community infrastructure.

The old DIY CRISPR tickles some, but it underwhelms others, namely, the developers of commercial applications. They prefer the new CRISPR—scalable, reliable, and deliverable.

The emerging field of synthetic biology—designing new biological components and systems—is revolutionizing medicine. Through the genetic programming of living cells, researchers are creating engineered systems that intelligently sense and respond to diverse environments, leading to more specific and effective solutions in comparison to current molecular-based therapeutics.

At the same time, cancer immunotherapy—using the body’s immune defenses to fight cancer—has transformed cancer treatment over the past decade, but only a handful of solid tumors have responded, and systemic therapy often results in significant side effects. Designing therapies that can induce a potent, anti–tumor immune response within a solid tumor without triggering systemic toxicity has posed a significant challenge.

Researchers at Columbia Engineering and Columbia University Irving Medical Center (CUIMC) announced today that they are addressing this challenge by engineering a strain of non–pathogenic bacteria that can colonize solid tumors in mice and safely deliver potent immunotherapies, acting as a Trojan Horse that treats tumors from within. The therapy led not only to complete tumor regression in a mouse model of lymphoma, but also significant control of distant, uninjected tumor lesions. Their findings are published today in Nature Medicine.

In biotech these days, CRISPR/Cas9 is a hot topic, because of its utility as a precise gene editing tool. Before humans repurposed it, CRISPR/Cas9 was a sort of internal immune system bacteria use to defend themselves against phages, or viruses that infect bacteria, by slicing up the phages’ DNA.

Scientists at Emory University School of Medicine and the Max Planck Unit for the Science of Pathogens have found that the “scissors” component of CRISPR/Cas9 sometimes gets stuck.

Cas9, an enzyme that cuts DNA, can also block gene activity without doing any cutting. In the pathogenic bacterium Francisella novicida, Cas9 regulates genes that need to be shut off for the bacteria to cause disease.

Some mice receiving a therapy that includes CRISPR gene editing appear to have been cured of HIV, but safety concerns must be overcome before human trials.